Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

C4 Therapeutics FY EPS $(2.67) Down From $(2.62) YoY, Sales $20.76M Down From $31.10M YoY

Author: Benzinga Newsdesk | February 22, 2024 08:19am
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(2.67) per share. This is a 1.91 percent decrease over losses of $(2.62) per share from the same period last year. The company reported $20.76 million in sales this quarter. This is a 33.25 percent decrease over sales of $31.10 million the same period last year.

Posted In: CCCC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist